NGM Bio Announces Proposed Offering of Common Stock
January 04, 2021 16:01 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors
December 09, 2020 16:05 ET
|
NGM Biopharmaceuticals, Inc.
LAIR1, through interactions with tumor-associated collagens, may form a stromal checkpoint that imposes signaling-based immune suppression and impedes anti-tumor immunityNGM plans to initiate...
NGM to Host Virtual R&D Day on December 9, 2020
November 16, 2020 12:05 ET
|
NGM Biopharmaceuticals, Inc.
– Event to showcase NGM’s multi-therapeutic area pipeline, including its oncology portfolio and Geographic Atrophy and NASH programs – – Planned presentations from NGM management, NGM scientists...
NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 Virtual
November 13, 2020 08:00 ET
|
NGM Biopharmaceuticals, Inc.
--Single and multiple intravitreal injections of NGM621 appeared safe and well tolerated in first-in-human study, with no patients experiencing serious adverse events, drug-related AEs, intraocular...
NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results
November 12, 2020 16:05 ET
|
NGM Biopharmaceuticals, Inc.
NGM continues to demonstrate the productivity of its research discovery engine and progress against its multi-therapeutic area pipeline: -- Initiated a Phase 2 clinical trial of NGM621, an...
NGM Bio to Present at Three Upcoming Investor Conferences
November 11, 2020 08:00 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
NGM Bio to Present Safety and Pharmacokinetics Data from Phase 1 Study of NGM621 in Patients with Geographic Atrophy at American Academy of Ophthalmology (AAO) 2020 Virtual
November 05, 2020 08:00 ET
|
NGM Biopharmaceuticals, Inc.
--Humanized IgG1 monoclonal antibody engineered to potently inhibit complement C3, with the potential for extended every eight-week dosing without pegylation-- --Phase 2 (CATALINA) study of...
NGM Bio Announces Multiple Aldafermin Presentations at Upcoming AASLD The Liver Meeting®, including Late-Breaking Oral Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH
November 04, 2020 08:00 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...
NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707, a Novel Dual Antagonist Antibody Inhibiting ILT2 and ILT4
October 19, 2020 07:00 ET
|
NGM Biopharmaceuticals, Inc.
ILT2 and ILT4, key myeloid and lymphoid checkpoints, may restrict anti-tumor immunity, enable tumors to evade immune detection and contribute to T cell checkpoint resistanceCompany plans to initiate...
NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollment Completed in Phase 2b ALPINE 2/3 Study
August 29, 2020 07:20 ET
|
NGM Biopharmaceuticals, Inc.
Late-breaker presentation selected as “Best of ILC”The 24-week Phase 2 study met its primary endpoint, achieving a statistically significant reduction in liver fat content (LFC), and robust fibrosis...